Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
low molecular weight sulfated dextran
- Development stage
- Unknown
- Lead developer
- Uppsala University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Low molecular weight sulfated dextran (LMW-SD) is a sulfated polysaccharide derivative investigated for its ability to inhibit the instant blood-mediated inflammatory reaction (IBMIR) in clinical islet transplantation. When pancreatic islets are infused into the portal vein of patients with type 1 diabetes, they trigger a rapid inflammatory and thrombotic response involving the activation of the coagulation and complement cascades, which leads to significant islet loss. LMW-SD acts as a potent inhibitor of both the complement and coagulation systems and also interferes with P-selectin-mediated cell adhesion. By mitigating these early inflammatory events, LMW-SD aims to improve the survival and engraftment of transplanted islets. It has been evaluated in Phase 2 clinical trials (such as CIT-01 and CIT-01B) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
- Other names
- sulfated dextranlow molecular weight dextran sulfate
02
Targets
Factor XIaSERPING1 (Serpin family G member 1)BB-031 (Von Willebrand factor)F2 (Thrombin)SELP (P-selectin)C1S (Complement component 1s subcomponent serine protease)F10 (Factor Xa)
Beyond the preview
Go deeper on low molecular weight sulfated dextran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on low molecular weight sulfated dextran.